Thiogenesis Therapeutics, Corp. (TTI.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.62 (-3.12%) as of
Key statistics
- Market cap
- 43.39M
- EPS (TTM)
- -0.1200
- Dividend yield
- 0.00%
- 52-week range
- 0.4400 – 0.8100
- Beta
- 0.61
- Profit margin
- 0.00%
- Volume
- 51.50k
About Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Toronto, ON, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.